[{"id":"ae82c4dd-4110-4d35-bde2-b1d7c85a910e","acronym":"CLEVER","url":"https://clinicaltrials.gov/study/NCT03408587","created_at":"2021-01-18T16:49:03.369Z","updated_at":"2024-07-02T16:35:48.958Z","phase":"Phase 1b","brief_title":"CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)","source_id_and_acronym":"NCT03408587 - CLEVER","lead_sponsor":"Viralytics","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Cavatak (gebasaxturev)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/29/2018","start_date":" 01/29/2018","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 05/22/2019","study_completion_date":" 05/22/2019","last_update_posted":"2023-05-04"},{"id":"d64bdc20-761b-48cc-84e6-438e0db27bd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02824965","created_at":"2021-01-18T13:51:06.943Z","updated_at":"2025-02-25T16:04:56.696Z","phase":"Phase 1/2","brief_title":"Pembrolizumab + CVA21 in Advanced NSCLC","source_id_and_acronym":"NCT02824965","lead_sponsor":"Olivia Newton-John Cancer Research Institute","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cavatak (gebasaxturev)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 07/01/2021","primary_completion_date":" 07/01/2021","study_txt":" Completion: 10/01/2021","study_completion_date":" 10/01/2021","last_update_posted":"2021-07-07"},{"id":"98747732-3518-4664-83fa-991317dc4663","acronym":"","url":"https://clinicaltrials.gov/study/NCT00438009","created_at":"2021-01-18T01:32:47.879Z","updated_at":"2024-07-02T16:36:58.499Z","phase":"Phase 1","brief_title":"A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)","source_id_and_acronym":"NCT00438009","lead_sponsor":"Viralytics","biomarkers":" ICAM1","pipe":"","alterations":" ","tags":["ICAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cavatak (gebasaxturev)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 05/16/2007","start_date":" 05/16/2007","primary_txt":" Primary completion: 08/28/2009","primary_completion_date":" 08/28/2009","study_txt":" Completion: 08/28/2009","study_completion_date":" 08/28/2009","last_update_posted":"2019-07-01"},{"id":"98cbca81-e256-4391-9c27-da6e1b03fe93","acronym":"PSX-X04","url":"https://clinicaltrials.gov/study/NCT00636558","created_at":"2021-01-18T02:22:10.111Z","updated_at":"2024-07-02T16:36:58.484Z","phase":"Phase 1","brief_title":"Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)","source_id_and_acronym":"NCT00636558 - PSX-X04","lead_sponsor":"Viralytics","biomarkers":" ICAM1","pipe":"","alterations":" ","tags":["ICAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cavatak (gebasaxturev)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 02/29/2008","start_date":" 02/29/2008","primary_txt":" Primary completion: 01/12/2012","primary_completion_date":" 01/12/2012","study_txt":" Completion: 01/12/2012","study_completion_date":" 01/12/2012","last_update_posted":"2019-07-01"}]